石药(01093.HK)一度急回9%近乎回吐本月升幅 为最差蓝筹
石药(01093.HK)今早开市微升至17.14元後突掉头向下,一度急跌9%至15.54元,跌穿10天线(16.2元)及20天线(15.85元),近乎全数回吐本月升幅。现时下挫逾8%报15.6元,暂为最差蓝筹,成交达8.4亿元,已显着超越昨日(10日)全日成交额。
另外,中生制药(01177.HK)亦紧随其後,逆市跌逾3%报10.48元,为第二差表现蓝筹。惟仍有医药股逆市造好,复星医药(02196.HK)微升0.2%报21.2元,国药(01099.HK)升1.6%报25.95元,中国中药(00570.HK)亦略升0.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.